Indian Journal of Drugs in Dermatology

REVIEW ARTICLE
Year
: 2021  |  Volume : 7  |  Issue : 1  |  Page : 12--14

Ligelizumab: A promising option on the horizon for the management of chronic spontaneous urticaria


Kiran Godse1, Anant D Patil2, Gauri Godse3 
1 Department of Dermatology, Dr. DY Patil Medical College, Nerul, Navi Mumbai, Maharashtra, India
2 Department of Pharmacology, Dr. DY Patil Medical College, Nerul, Navi Mumbai, Maharashtra, India
3 Shree Skin Centre, Nerul, Navi Mumbai, Maharashtra, India

Correspondence Address:
Anant D Patil
Department of Pharmacology, Dr. DY Patil Medical College, Nerul, Navi Mumbai - 400 706, Maharashtra
India

Chronic spontaneous urticaria may pose challenges for the treatment in some patients. Different options for the management of chronic urticaria include second-generation antihistamines, leukotriene receptor antagonists, omalizumab (anti-IgE antibody), and immunosuppressants. Omalizumab, a monoclonal antibody, is a valuable option for patients not responding to up-dosing (up to 4 times) of second-generation antihistamine. However, in about one-fourth of the patients, omalizumab may not be effective in controlling symptoms. Considering this, there is a need to identify the drugs for effective treatment. Ligelizumab is a novel anti-IgE monoclonal antibody with higher affinity to IgE than omalizumab. In phase 2b clinical trial, it is found to be effective and well tolerated in patients with chronic spontaneous urticaria. When approved, it may be beneficial for patients who cannot receive or have suboptimal efficacy with omalizumab.


How to cite this article:
Godse K, Patil AD, Godse G. Ligelizumab: A promising option on the horizon for the management of chronic spontaneous urticaria.Indian J Drugs Dermatol 2021;7:12-14


How to cite this URL:
Godse K, Patil AD, Godse G. Ligelizumab: A promising option on the horizon for the management of chronic spontaneous urticaria. Indian J Drugs Dermatol [serial online] 2021 [cited 2021 Nov 27 ];7:12-14
Available from: https://www.ijdd.in/article.asp?issn=2455-3972;year=2021;volume=7;issue=1;spage=12;epage=14;aulast=Godse;type=0